1.77

2.91% 0.05

After Hours: 1.78 0.01 +0.56%

Pacific Biosciences Of California Inc (PACB)

Overview News Price History Option Chain Financials Why PACB Down? Discussions Forecast

Pacific Biosciences Of California Inc stock is traded at $1.77, with a volume of 8.01M. It is up +2.91% in the last 24 hours and down -3.80% over the past month. Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Previous Close:

$1.72

Open:

$1.74

24h Volume:

8.01M

Relative Volume:

0.87

Market Cap:

$484.74M

Revenue:

$188.87M

Net Income/Loss:

$-400.38M

P/E Ratio:

-1.3937

EPS:

-1.27

Net Cash Flow:

$-260.90M

1W Performance:

-4.58%

1M Performance:

-3.80%

6M Performance:

-3.28%

1Y Performance:

-78.62%

1-Day Range:

$1.695

$1.84

1-Week Range:

$1.49

$1.88

52-Week Range:

$1.16

$10.65

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name

Pacific Biosciences Of California Inc

Sector

Healthcare (1195)

Industry

Medical Devices (153)

Phone

650-521-8000

Address

1305 O'BRIEN DRIVE, MENLO PARK, CA

Employee

796

Twitter

@pacbio

Next Earnings Date

2024-11-07

Latest SEC Filings

PACB's Discussions on Twitter

Compare PACB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PACB	1.77	484.74M	188.87M	-400.38M	-260.90M	-1.27
ABT	117.26	201.11B	41.22B	5.77B	6.49B	2.94
SYK	390.14	148.40B	21.97B	3.59B	3.21B	6.74
BSX	91.50	134.72B	15.91B	1.79B	1.89B	0.82
MDT	84.74	108.57B	33.00B	4.29B	5.50B	2.71
EW	70.38	41.51B	6.60B	4.16B	490.10M	2.34

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-14-23	Initiated	Stephens	Overweight
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-17-23	Upgrade	UBS	Neutral → Buy
Oct-31-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Jul-05-23	Resumed	JP Morgan	Overweight
Jun-30-23	Initiated	Goldman	Buy
May-10-23	Initiated	Barclays	Equal Weight
Mar-31-23	Upgrade	TD Cowen	Market Perform → Outperform
Feb-02-23	Initiated	UBS	Neutral
Jan-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-21-22	Resumed	Cantor Fitzgerald	Overweight
Jan-06-22	Resumed	Piper Sandler	Neutral
Oct-15-21	Resumed	Cowen	Market Perform
Sep-27-21	Initiated	Canaccord Genuity	Buy
Feb-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Nov-03-20	Downgrade	Piper Sandler	Overweight → Neutral
Oct-02-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight
Mar-09-20	Resumed	Cantor Fitzgerald	Overweight
Oct-15-19	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-02-19	Downgrade	Stephens	Overweight → Equal-Weight
Oct-19-18	Initiated	Cowen	Outperform
Nov-03-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-28-17	Downgrade	CL King	Buy → Neutral
Nov-03-16	Reiterated	Cantor Fitzgerald	Buy
Jun-27-16	Initiated	CL King	Buy
Apr-15-16	Initiated	First Analysis Sec	Overweight
Feb-04-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jan-04-16	Reiterated	Cantor Fitzgerald	Buy
Oct-23-15	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-27-15	Initiated	Cantor Fitzgerald	Buy
Feb-04-15	Reiterated	Maxim Group	Buy
Sep-26-13	Reiterated	Maxim Group	Buy
Jan-14-13	Reiterated	Maxim Group	Buy

View All

Pacific Biosciences Of California Inc Stock (PACB) Latest News

Nov 20, 2024

PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN

Nov 20, 2024

Nov 19, 2024